3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Melanoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Ganglioneuroblastoma
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
91
Carboplatin
73
Pemetrexed
58
Nivolumab
50
Docetaxel
47
Cisplatin
47
Paclitaxel
46
Erlotinib Hydrochloride
37
Radiotherapy
30
Gemcitabine
27
osimertinib
23
Cetuximab
23
Bevacizumab
21
Ipilimumab
18
Radiosurgery
14
130-nm albumin-bound paclitaxel
14
Taxes
13
Gefitinib
13
Cyclophosphamide
13
avelumab
12
atezolizumab
12
durvalumab
11
Albumin-Bound Paclitaxel
11
cemiplimab
9
Radiation
8
Drug Therapy
8
alectinib
7
Injections
7
Etoposide
7
trametinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Non-Small-Cell Lung
×
Colony-Stimulating Factors
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled